m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05960
 [1]
m6A modification DANCR DANCR LRPPRC : m6A sites Direct Enhancement Non-coding RNA DANCR PLAU  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Leucine-rich PPR motif-containing protein, mitochondrial (LRPPRC) READER
 Regulator Info 
m6A Target Differentiation antagonizing non-protein coding RNA (DANCR)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Differentiation antagonizing non-protein coding RNA (DANCR) LncRNA View Details
Regulated Target Urokinase-type plasminogen activator (PLAU) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Differentiation antagonizing non-protein coding RNA (DANCR) activated IL-11-STAT3 signaling and increased CCND1 and Urokinase-type plasminogen activator (PLAU) expression via guiding leucine-rich pentatricopeptide repeat containing (LRPPRC) to stabilize mRNA.
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Responsed Drug BP-1-102
 Drug Info 
Pathway Response JAK-STAT signaling pathway hsa04630
Cell Process Cell migration
Cell invasion
Cell proliferation
mRNA stability
In-vitro Model
 UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
T24 Bladder carcinoma Homo sapiens CVCL_0554
HEK293T Normal Homo sapiens CVCL_0063
In-vivo Model Ten mice were included in each group, and lentivirus-transduced UM-UC-3 cells (3 × 106 cells) that stably expressed firefly luciferase were inoculated into the mice's footpads.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Urokinase-type plasminogen activator (PLAU) 42 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Pro-urokinase Approved [2]
Synonyms
Thrombolyse (TN)
    Click to Show/Hide
MOA Modulator
External Link
TTD: D03VNX
 Compound Name Urokinase Approved [3]
MOA Modulator
External Link
TTD: D0E8UO
 Compound Name PAI-1 Phase 4 [4]
Synonyms
PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3246941
TTD: D03ZJE
DrugBank: DB08324
 Compound Name Amediplase Phase 3 [5]
Synonyms
Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
    Click to Show/Hide
MOA Activator
External Link
CID: 154656
TTD: D0G6ZG
 Compound Name Upamostat Phase 2 [6]
Synonyms
WX-671
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 410 nM
External Link
CID: 9830667
TTD: D03KGH
 Compound Name Saruplase Phase 2 [7]
Synonyms
Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal
    Click to Show/Hide
MOA Activator
External Link
TTD: D0G5UW
 Compound Name HTU-PA Phase 1/2 [8]
Synonyms
Human tissue urokinase type plasminogen activator, Global Biotech
    Click to Show/Hide
MOA Activator
External Link
TTD: D01HHJ
 Compound Name PMID18163548C4 Clinical trial [9]
Synonyms
7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 20 nM
External Link
CID: 449051
TTD: D00EPS
 Compound Name UK-356202 Clinical trial [10]
Synonyms
compound 13j [PMID: 15149680]; UK-356,202
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 37 nM
External Link
CID: 9885167
TTD: D0G0YZ
 Compound Name PAI-2 Discontinued in Phase 2 [11]
Synonyms
N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 443433
TTD: D0D3VA
 Compound Name WX-UK1 Discontinued in Phase 1/2 [12]
Synonyms
UKI-1; UNII-00LOF6890B; CHEMBL107955; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 960 nM
External Link
CID: 9895194
TTD: D08INO
 Compound Name B-428 Terminated [13]
MOA Inhibitor
Activity Ki = 79.43 nM
External Link
CID: 1747
TTD: D0K1PR
 Compound Name UPA-targeted oncolytic Sendai virus Investigative [2]
Synonyms
BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D00LDI
 Compound Name CRA_10655 Investigative [14]
Synonyms
AC1O4QGF
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 220 nM
External Link
CID: 447480
TTD: D01LCS
DrugBank: DB02526
 Compound Name 5-Methylsulfanyl-thiophene-2-carboxamidine Investigative [15]
Synonyms
CHEMBL28890; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 6000 nM
External Link
CID: 10313318
TTD: D02XJW
 Compound Name ATN-658 Investigative [2]
Synonyms
ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin
    Click to Show/Hide
MOA Activator
External Link
TTD: D03BWQ
 Compound Name (2R)-1-(2,6-dimethylphenoxy)propan-2-amine Investigative [14]
Synonyms
94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 > 1000000 nM
External Link
CID: 180621
TTD: D03NLL
DrugBank: DB07129
 Compound Name B-623 Investigative [16]
Synonyms
149732-37-6
    Click to Show/Hide
MOA Modulator
Activity Ki = 530 nM
External Link
CID: 9820186
TTD: D05DNW
 Compound Name 4-chloro-1-guanidino-7-isoquinolinesulphonamide Investigative [17]
Synonyms
223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 140 nM
External Link
CID: 16658353
TTD: D06CJP
 Compound Name 2-Amino-5-Hydroxy-Benzimidazole Investigative [18]
MOA Inhibitor
Activity IC50 = 200000 nM
External Link
CID: 162636
TTD: D09KKF
DrugBank: DB03729
 Compound Name 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine Investigative [18]
Synonyms
CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 630 nM
External Link
CID: 447732
TTD: D0A8WP
DrugBank: DB01977
 Compound Name Thieno[2,3-B]Pyridine-2-Carboxamidine Investigative [14]
Synonyms
amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5438
TTD: D0B1AK
DrugBank: DB03876
 Compound Name Recombinant human pro-urokinase Investigative [2]
Synonyms
Recombinant human pro-urokinase (myocardial infarction)
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0D1TX
 Compound Name N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea Investigative [18]
Synonyms
AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 4286
TTD: D0EV6B
DrugBank: DB03782
 Compound Name (4-guanidino-benzyl)-carbamic acid benzyl ester Investigative [19]
Synonyms
CHEMBL391969
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 16000 nM
External Link
CID: 44436702
TTD: D0F6EZ
 Compound Name 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine Investigative [14]
Synonyms
SCHEMBL20553177; DB07122
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16758228
TTD: D0ZM9M
DrugBank: DB07122
 Compound Name 4-methoxy-N'-(2-phenylacetyl)benzohydrazide Investigative [20]
Synonyms
4-methoxy-N'-(phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2500 nM
External Link
CID: 695069
TTD: D02AKP
 Compound Name ATF-HI-8 Investigative [21]
Synonyms
urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05ABK
 Compound Name 1-guanidino-7-isoquinolinesulphonamide Investigative [17]
Synonyms
SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 280 nM
External Link
CID: 16658352
TTD: D0K4PK
 Compound Name CRA_8696 Investigative [14]
Synonyms
AC1O4QGN
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 8 nM
External Link
CID: 447476
TTD: D0K7YL
DrugBank: DB03159
 Compound Name 1-guanidino-N-phenyl-7-isoquinolinesulphonamide Investigative [17]
Synonyms
SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 160 nM
External Link
CID: 16658631
TTD: D00PEJ
 Compound Name (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone Investigative [20]
Synonyms
BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1300 nM
External Link
CID: 674641
TTD: D00WFQ
 Compound Name 4-iodobenzo[b]thiophene 2-carboxamidine Investigative [22]
Synonyms
amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1746
TTD: D05MJU
DrugBank: DB03136
 Compound Name (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative [20]
Synonyms
BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18200 nM
External Link
CID: 674651
TTD: D06LPR
 Compound Name 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine Investigative [23]
Synonyms
(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1300 nM
External Link
CID: 6852210
TTD: D0SP2I
 Compound Name (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative [20]
Synonyms
AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1700 nM
External Link
CID: 674656
TTD: D05ZIP
 Compound Name Benzamidine Investigative [18]
Synonyms
Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 180000 nM
External Link
CID: 2332
TTD: D07SFI
 Compound Name (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative [20]
Synonyms
(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3100 nM
External Link
CID: 699665
TTD: D08OCS
 Compound Name 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide Investigative [20]
Synonyms
AC1LERN1; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1500 nM
External Link
CID: 716930
TTD: D0IU5E
 Compound Name (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone Investigative [20]
Synonyms
AC1LDSBN; BAS 02052919; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2600 nM
External Link
CID: 674628
TTD: D0X1OY
 Compound Name 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Investigative [24]
Synonyms
amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1507
TTD: D08OLP
DrugBank: DB02463
 Compound Name Fucose Investigative [18]
Synonyms
L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 17106
TTD: D0G6XS
2C94: Bladder cancer 83 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Enfortumab vedotin Phase 3 [25]
Synonyms
Padcev
    Click to Show/Hide
External Link
TTD: DAG87H
 Compound Name Atezolizumab Approved [26]
External Link
TTD: D0YM2K
 Compound Name Halaven Phase 1/2 [26]
Synonyms
Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent
    Click to Show/Hide
External Link
CID: 17755248
TTD: D0XQ5X
 Compound Name RG-7446 Approved [27]
External Link
TTD: D0OZ4J
 Compound Name Pemigatinib Approved [26]
Synonyms
Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828
    Click to Show/Hide
External Link
CID: 86705695
TTD: D0O6UY
DrugBank: DB15102
 Compound Name Erdafitinib Approved [28]
Synonyms
1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino
    Click to Show/Hide
External Link
CID: 67462786
TTD: D0NW0T
DrugBank: DB12147
 Compound Name Hexyl aminolevulinate Approved [29]
Synonyms
Hexvix (TN)
    Click to Show/Hide
External Link
CID: 6433082
TTD: D0AY9Q
 Compound Name BCG vaccine Approved [29]
Synonyms
OncoTice; TiceBCG; BCG vaccine, Organon
    Click to Show/Hide
External Link
TTD: D0A8LZ
 Compound Name Valrubicin Approved [30]
Synonyms
Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
    Click to Show/Hide
External Link
CID: 454216
TTD: D07IPB
DrugBank: DB00385
 Compound Name Vicineum Phase 3 [31]
Synonyms
Oportuzumab monatox
    Click to Show/Hide
External Link
TTD: DRP4Q9
 Compound Name Sasanlimab Phase 3 [32]
Synonyms
PF-06801591
    Click to Show/Hide
External Link
TTD: DP2Z0X
 Compound Name CG0070 Phase 3 [33]
Synonyms
CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys
    Click to Show/Hide
External Link
TTD: D7EZ0H
 Compound Name Nadofaragene firadenovec Phase 3 [26]
External Link
TTD: D0X4TK
 Compound Name Oportuzumab monatox Phase 3 [33]
External Link
TTD: D0OF1R
 Compound Name Apaziquone Phase 3 [34]
Synonyms
EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin
    Click to Show/Hide
External Link
CID: 5813717
TTD: D0FP0R
DrugBank: DB12593
 Compound Name Tesetaxel Phase 2 [35]
Synonyms
DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
    Click to Show/Hide
External Link
CID: 6918574
TTD: D0F9VH
DrugBank: DB12019
 Compound Name EN3488 Phase 3 [36]
External Link
TTD: D09KHE
 Compound Name NKTR 214 Phase 3 [33]
External Link
TTD: D02QQE
 Compound Name Ramucirumab Phase 3 [26]
External Link
TTD: D01QWT
 Compound Name Vicinium Phase 3 [26]
External Link
TTD: D00RTC
 Compound Name ICP-192 Phase 2 [37]
External Link
TTD: DZM65T
 Compound Name Inodiftagene vixteplasmid Phase 2 [38]
Synonyms
BC-819
    Click to Show/Hide
External Link
TTD: DE2V3Y
 Compound Name CPX-POM Phase 2 [39]
External Link
TTD: D7K3FB
 Compound Name LY3012212 Phase 2 [40]
Synonyms
Icrucumab
    Click to Show/Hide
External Link
TTD: D0X2RL
 Compound Name CV-301 Phase 2 [26]
External Link
TTD: D0W8FE
 Compound Name ABI-009 Phase 2 [26]
External Link
TTD: D0W3UV
 Compound Name ALT-801 Phase 2 [33]
Synonyms
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
    Click to Show/Hide
External Link
TTD: D0V5JH
 Compound Name INO-5401 Phase 2 [26]
External Link
TTD: D0P2ME
 Compound Name RX-3117 Phase 2 [26]
Synonyms
Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
    Click to Show/Hide
External Link
CID: 11242315
TTD: D0L7WS
 Compound Name BC-819 Phase 2 [41]
External Link
TTD: D0K0KQ
 Compound Name IPI-549 Phase 2 [42]
Synonyms
XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((
    Click to Show/Hide
External Link
CID: 91933883
TTD: D0I3LO
 Compound Name B-701 Phase 2 [26]
Synonyms
VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester
    Click to Show/Hide
External Link
CID: 95987
TTD: D0G6CF
 Compound Name NC-6004 Phase 2 [26]
External Link
TTD: D0FG2Z
 Compound Name ALT-803 Phase 2 [26]
Synonyms
IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
    Click to Show/Hide
External Link
TTD: D0FD7H
 Compound Name Vesigenurtacel-L Phase 2 [43]
External Link
TTD: D0E8QE
 Compound Name BAY1163877 Phase 2 [44]
Synonyms
Rogaratinib
    Click to Show/Hide
External Link
CID: 71611869
TTD: D0E8PR
DrugBank: DB15078
 Compound Name Coxsackievirus A21 Phase 1/2 [33]
Synonyms
Cavatak (TN)
    Click to Show/Hide
External Link
TTD: D0C4BL
 Compound Name OGX-427 Phase 2 [45]
External Link
CID: 71710946
TTD: D0AX1N
 Compound Name PIRITREXIM Phase 2 [46]
Synonyms
72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine
    Click to Show/Hide
External Link
CID: 54369
TTD: D09AYQ
DrugBank: DB03695
 Compound Name VesiGel Phase 2 [26]
External Link
TTD: D08LYZ
 Compound Name Instiladrin Phase 2 [47]
External Link
TTD: D07CNY
 Compound Name CDX-1307 Phase 2 [48]
Synonyms
BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics
    Click to Show/Hide
External Link
TTD: D04REV
 Compound Name APR-246 Phase 2 [49]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name MV-NIS Phase 1 [26]
Synonyms
MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc
    Click to Show/Hide
External Link
TTD: D01IJJ
 Compound Name 4SCAR-PSMA Phase 1/2 [50]
External Link
TTD: D0VI8T
 Compound Name MAGE-A10 TCR Phase 1/2 [26]
External Link
TTD: D0L1CO
 Compound Name Lx-TB-PstS1 Phase 1/2 [51]
Synonyms
Lx-Bladder
    Click to Show/Hide
External Link
TTD: D0H7LN
 Compound Name 4SCAR-FRa Phase 1/2 [50]
External Link
TTD: D09NUH
 Compound Name ABY-025 Phase 1/2 [52]
External Link
TTD: D08KCJ
 Compound Name ADP-A2M10 Phase 1 [53]
External Link
TTD: DM38KC
 Compound Name TAR-200 Phase 1 [26]
External Link
TTD: D0WM3D
 Compound Name ASG-15ME Phase 1 [54]
External Link
TTD: D0UM4S
 Compound Name Vesimune Phase 2 [55]
External Link
TTD: D0S0ZQ
 Compound Name NEO-PV-01 Phase 1 [26]
External Link
TTD: D0Q6AU
 Compound Name Neo-Urinary Conduit Phase 1 [56]
External Link
TTD: D0B6LP
 Compound Name FPA144 Phase 1 [33]
External Link
TTD: D06NND
 Compound Name Ad-IFN-alpha Phase 1 [57]
Synonyms
Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI
    Click to Show/Hide
External Link
TTD: D03QWG
 Compound Name LNK-754 Phase 1 [58]
Synonyms
LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-
    Click to Show/Hide
External Link
CID: 46208720
TTD: D03BXU
DrugBank: DB12640
 Compound Name example 7 [US8664233] Clinical trial [59]
Synonyms
SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole
    Click to Show/Hide
External Link
CID: 24990553
TTD: D0Y9FX
 Compound Name (S)-DRF-1042 Clinical trial [60]
Synonyms
5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT
    Click to Show/Hide
External Link
CID: 91623363
TTD: D0M8KY
 Compound Name Larotaxel Discontinued in Phase 3 [61]
Synonyms
Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881
    Click to Show/Hide
External Link
CID: 6918260
TTD: D0J0RV
DrugBank: DB12984
 Compound Name Keyhole limpet hemocyanin Discontinued in Phase 3 [62]
External Link
TTD: D07UQR
 Compound Name IDM-2 Discontinued in Phase 2/3 [63]
Synonyms
Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma
    Click to Show/Hide
External Link
TTD: D0YW4R
 Compound Name NKS-01 Discontinued in Phase 2 [64]
Synonyms
14alpha-Hydroxy-4-androstene-3,6,17-trione
    Click to Show/Hide
External Link
CID: 6918079
TTD: D0U9LL
 Compound Name S-288310 Discontinued in Phase 1/2 [65]
Synonyms
Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi
    Click to Show/Hide
External Link
TTD: D0Z2KU
 Compound Name Capzola Application submitted [26]
External Link
TTD: D0VO7K
 Compound Name MINAMESTANE Terminated [66]
Synonyms
FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione
    Click to Show/Hide
External Link
CID: 65886
TTD: D0FS9K
 Compound Name CG-8840 Terminated [67]
Synonyms
CV-884
    Click to Show/Hide
External Link
TTD: D02GJE
 Compound Name ET-009 Investigative [68]
External Link
TTD: D0XT3G
 Compound Name TD-6989 Investigative [68]
External Link
TTD: D0V9BX
 Compound Name SL-601 Investigative [68]
External Link
TTD: D0QI1O
 Compound Name ASC-JMZ1 Investigative [68]
External Link
TTD: D0O0II
 Compound Name TD-3633 Investigative [68]
External Link
TTD: D0A5KO
 Compound Name CEL-011 Investigative [68]
External Link
TTD: D09TSX
 Compound Name Debio-1141 Investigative [68]
Synonyms
PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm
    Click to Show/Hide
External Link
TTD: D09OLR
 Compound Name TD-1770 Investigative [68]
External Link
TTD: D08VWJ
 Compound Name Chitosan/IL-12 Investigative [68]
Synonyms
Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute
    Click to Show/Hide
External Link
TTD: D08UZA
 Compound Name BAMLET Investigative [68]
Synonyms
BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune
    Click to Show/Hide
External Link
TTD: D07FCA
 Compound Name TMX-202 Investigative [69]
Synonyms
TMX-20X
    Click to Show/Hide
External Link
TTD: D05TCC
 Compound Name SX-MTR1 Investigative [70]
Synonyms
MTOR modulators (small peptide mimetics, bladder cancer), Serometrix
    Click to Show/Hide
External Link
TTD: D05SOW
 Compound Name AP-300 Investigative [68]
External Link
TTD: D03KIK
 Compound Name BC-821 Investigative [68]
Synonyms
IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell
    Click to Show/Hide
External Link
TTD: D03IQK
 Compound Name OGX-427 + Paclitaxel Investigative [71]
External Link
CID: 91866823
TTD: D00ZBZ
References
Ref 1 DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression. Mol Ther. 2019 Feb 6;27(2):326-341. doi: 10.1016/j.ymthe.2018.12.015. Epub 2019 Jan 9.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 4 Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6. doi: 10.1093/jnci/87.10.751.
Ref 5 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. doi: 10.1517/14728214.11.1.75.
Ref 6 Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70. doi: 10.1038/bjc.2013.62. Epub 2013 Feb 14.
Ref 7 Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
Ref 8 Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
Ref 9 Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6. doi: 10.1021/jm701359z. Epub 2007 Dec 29.
Ref 10 Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. doi: 10.1016/j.bmcl.2004.03.094.
Ref 11 Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41. doi: 10.1002/(sici)1097-0320(20000501)40:1<32::aid-cyto5>3.0.co;2-z.
Ref 12 Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. doi: 10.1002/ijc.20192.
Ref 13 Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol. 2000;477:331-41. doi: 10.1007/0-306-46826-3_36.
Ref 14 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 15 Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):491-5. doi: 10.1016/s0960-894x(01)00787-9.
Ref 16 Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 1999 May-Jun;6(3):523-6. doi: 10.3892/or.6.3.523.
Ref 17 Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. doi: 10.1021/jm061066t. Epub 2007 Apr 21.
Ref 18 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 19 Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J Med Chem. 2007 Dec 27;50(26):6638-46. doi: 10.1021/jm700962j. Epub 2007 Dec 1.
Ref 20 N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. doi: 10.1021/jm070600+. Epub 2007 Sep 12.
Ref 21 Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361-6. doi: 10.1074/jbc.270.14.8361.
Ref 22 Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol. 2000 Apr;7(4):299-312. doi: 10.1016/s1074-5521(00)00104-6.
Ref 23 Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26. doi: 10.1021/jm051272l.
Ref 24 Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. J Med Chem. 2001 Aug 16;44(17):2753-71. doi: 10.1021/jm0100638.
Ref 25 ClinicalTrials.gov (NCT03474107) An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). U.S.National Institutes of Health.
Ref 26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034572)
Ref 28 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 30 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 31 Clinical pipeline report, company report or official report of Sesen Bio.
Ref 32 ClinicalTrials.gov (NCT04165317) Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST). U.S. National Institutes of Health.
Ref 33 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 34 ClinicalTrials.gov (NCT00598806) Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant for Noninvasive Bladder Cancer. U.S. National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT00406068) Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT04492293) An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer. U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT03719300) Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC. U.S. National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT04525131) Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors. U.S. National Institutes of Health.
Ref 40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024862)
Ref 41 ClinicalTrials.gov (NCT01413087) Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT03980041) Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275). U.S. National Institutes of Health.
Ref 43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039425)
Ref 44 ClinicalTrials.gov (NCT04040725) Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
Ref 46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7414).
Ref 47 ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
Ref 48 ClinicalTrials.gov (NCT01094496) A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study). U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT03185468) Intervention of Bladder Cancer by CAR-T
Ref 51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031541)
Ref 52 ClinicalTrials.gov (NCT01858116) PET Study of Breast Cancer Patients Using [68Ga]ABY-025. U.S. National Institutes of Health.
Ref 53 Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.
Ref 54 ClinicalTrials.gov (NCT01963052) ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer. U.S. National Institutes of Health.
Ref 55 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025521)
Ref 57 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
Ref 58 A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 1;10(21):7127-35.
Ref 59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8283).
Ref 60 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8261).
Ref 61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227)
Ref 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001940)
Ref 63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014822)
Ref 64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003076)
Ref 65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031637)
Ref 66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002545)
Ref 67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016289)
Ref 68 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 69 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).
Ref 70 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
Ref 71 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.